Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Benzenesulfonates
  • Gastrointestinal Stromal Tumors
  • Mutation
  • Piperazines
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins c-kit
  • Pyridines
  • Pyrimidines

abstract

  • Our results emphasize the need for tailored salvage therapy in imatinib-refractory gastrointestinal stromal tumors according to individual molecular mechanisms of resistance. The Ba/F3 KIT(WK557-8del/T670I) cells were sensitive only to sorafenib inhibition, whereas nilotinib was more potent on imatinib-resistant KIT(V560del/V654A) and KIT(V559D/D820Y) mutant cells than dasatinib and sorafenib.

publication date

  • August 15, 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-07-0484

PubMed ID

  • 17699867

Additional Document Info

start page

  • 4874

end page

  • 81

volume

  • 13

number

  • 16